SCHEMBL7542553

SCHEMBL7542553

CN(CCOc1ccc(CC(Cc2ccc(C(=O)O)cc2)C(=O)C(F)(F)F)cc1)C(C)(c1ccc(Cl)cc1)c1ccc(Cl)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR4A2 P43354 2/20 0.43
▸ BCL2 P10415 2/20 0.42
▸ RXRA P19793 2/20 0.41
▸ RXRB P28702 2/20 0.41
▸ PPARG P37231 1/20 0.40
▸ PPARA Q07869 1/20 0.40
▸ CNR1 P21554 2/20 0.40
▸ EIF4E P06730 1/20 0.39
▸ MAOB P27338 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ ATM Q13315 1/20 0.38
▸ CNR2 P34972 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ HRH3 Q9Y5N1 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ EBP Q15125 1/20 0.37
▸ SIGMAR1 Q99720 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7539911 0.90 ATM (0.40) PPARGPPARACNR1MAOBMEN1
SCHEMBL7538938 0.89 NR4A2 (0.45) NR4A2BCL2RXRARXRBPPARG
SCHEMBL7538926 0.88 CNR1 (0.40) NR4A2BCL2RXRARXRBPPARG
SCHEMBL7538923 0.86 MAOB (0.41) PPARGPPARACNR1MAOBMEN1
SCHEMBL7537800 0.86 MAOB (0.40) RXRAPPARGPPARACNR1MAOB
SCHEMBL7542604 0.85 PPARG (0.41) PPARGPPARACNR1MAOBMEN1
SCHEMBL7535741 0.84 PPARG (0.44) PPARGPPARACNR1MAOBMEN1
SCHEMBL7542549 0.83 MEN1 (0.48) NR4A2BCL2RXRARXRBCNR1
SCHEMBL7542557 0.83 MAOB (0.35) PPARGPPARACNR1MAOBMEN1
SCHEMBL7535851 0.82 PPARG (0.44) PPARGPPARACNR1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6414179-B1 USEFUL AGENTS IN THE TREATMENT OF INFLAMMATORY DISEASES SUCH AS ASTHMA, ARTHRITIS, INFLAMMATORY BOWEL DISEASE AND NEURODEGENERATIVE DISEASES BRISTOL-MYERS SQUIBB COMPANY 2002-07-02 — — US disclosed
US-20020065246-A1 Alpha-and beta- substituted trifluoromethyl ketones as phospholipase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2002-05-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020065246-A1 Alpha-and beta- substituted trifluoromethyl ketones as phospholipase inhibitors PLA2G4B, PLA2G1B, PLA2R1 NR4A2 1681/4885BCL2 2376/4885RXRA 934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback